The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
Metastatic melanoma is near-to-invariably a fatal disease. As novel therapeutic strategies against metastatic melanoma are urgently needed, we have tested a combinatorial regimen consisting of conventional chemotherapy coupled to bevacizumab, a monoclonal antibody that inhibit angiogenesis, demonstr...
| Main Authors: | , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Landes Bioscience
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667915/ |